Results 11 to 20 of about 56,406 (298)
The current and future state of companion diagnostics [PDF]
Pharmacogenomics and Personalized Medicine, 2015 Amit Agarwal,1 Dan Ressler,2 Glenn Snyder1 1Deloitte Consulting LLP, San Francisco, CA, USA; 2Deloitte Consulting LLP, Philadelphia, PA, USA Abstract: Companion diagnostics are an indispensable part of personalized medicine and will likely continue to ...
Agarwal A, Ressler D, Snyder G
doaj +2 more sources
Companion diagnostics-a tool to improve pharmacotherapy. [PDF]
Ann Transl Med, 2016 The variability of pharmacotherapy can be of a significant magnitude, and the main reason for this is often diseases heterogeneity. Patients who have similar diagnoses very often respond differently to the same pharmacological intervention, with great variability in both efficacy and safety outcome.
Jørgensen JT, Hersom M.
europepmc +5 more sources
An analysis of FDA drug approvals for oncological hematological malignancies in relation to companion diagnostics [PDF]
Frontiers in OncologyJan Trøst Jørgensen
doaj +2 more sources
BMC Cancer, 2021 Background MutL Homolog 1 (MLH1) promotor methylation is associated with microsatellite instability high colorectal cancer (CRC). The strong correlation between methylation status and cancer development and progression has led to a growing interest in ...
Danyi Wang +5 more
doaj +1 more source
Multiplexed Prostate Cancer Companion Diagnostic Devices [PDF]
Sensors, 2021 Prostate cancer (PCa) remains one of the most prominent forms of cancer for men. Since the early 1990s, Prostate-Specific Antigen (PSA) has been a commonly recognized PCa-associated protein biomarker. However, PSA testing has been shown to lack in specificity and sensitivity when needed to diagnose, monitor and/or treat PCa patients successfully.
Josephine Aidoo-Brown +2 more
openaire +4 more sources
Factor VIII companion diagnostic for haemophilia [PDF]
Frontiers in Bioengineering and Biotechnology, 2022 Haemophilia is predominantly an inherited disorder that impairs the body’s ability to make blood clots, a process needed to stop bleeding. The condition of this disease is complex to manage, but many patients do so through home therapy and often only see their core multidisciplinary healthcare team annually.
Hu, Chunxiao +4 more
openaire +3 more sources
Alternate Antimicrobial Therapies and Their Companion Tests
Diagnostics, 2023 New antimicrobial approaches are essential to counter antimicrobial resistance. The drug development pipeline is exhausted with the emergence of resistance, resulting in unsuccessful trials.
Sriram Kalpana +4 more
doaj +1 more source
Are Companion Diagnostics Useful? [PDF]
Clinical Chemistry, 2013 We define a companion diagnostics (CDx)5 test as any diagnostic tool that guides the selection of patient treatment. In the US, these tests include diagnostics cleared by the Food and Drug Administration (FDA), as well as laboratory-developed tests (LDTs) run in CLIA-accredited laboratories.
J Carl, Barrett +4 more
openaire +2 more sources
FOXM1 coming of age: time for translation into clinical benefits? [PDF]
, 2012 A decade since the first evidence implicating the cell cycle transcription factor Forkhead Box M1 (FOXM1) in human tumorigenesis, a slew of subsequent studies revealed an oncogenic role of FOXM1 in the majority of human cancers including oral ...
Teh, M-T
core +1 more source
Leukocyte CH25H is a potential diagnostic and prognostic marker for lung adenocarcinoma
Scientific Reports, 2022 Metastasis, a major challenge during the treatment of lung cancer, causes deterioration in patient health outcomes. Thus, to address this problem, this study aimed to explore the role and contribution of Cholesterol 25-Hydroxylase (CH25H) as a potential ...
Jun Zhang +14 more
doaj +1 more source